A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Administration of the CD28 superagonistic antibody JJ316 is an efficient means to treat autoimmune diseases in rats, but the humanized antibody TGN1412 caused devastating side effects in healthy volunteers during a clinical trial. Here we show that JJ316 treatment of rats induced a dramatic redistribution of T lymphocytes from the periphery to the secondary lymphoid organs, resulting in severe T lymphopenia. Live imaging of secondary lymphoid organs revealed that JJ316 administration almost instantaneously (<2 minutes) arrested T cells in situ. This reduction in T cell motility was accompanied by profound cytoskeletal rearrangements and increased cell size. In addition, surface expression of lymphocyte function-associated antigen-1 was enhanced, endothelial differentiation sphingolipid G protein-coupled receptor 1 and L selectin levels were downregulated, and the cells lost their responsiveness to sphingosine 1-phosphate-directed migration. These proadhesive alterations were accompanied by signs of strong activation, including upregulation of CD25, CD69, CD134, and proinflammatory mediators. However, this did not lead to a cytokine storm similar to the clinical trial. While most of the early changes disappeared within 48 hours, we observed that CD4+CD25+FoxP3+ regulatory T cells experienced a second phase of activation, which resulted in massive cell enlargement, extensive polarization, and increased motility. These data suggest that CD28 superagonists elicit 2 qualitatively distinct waves of activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The first wave of T cell activation and redistribution was characterized by elevated levels of proinflammatory cytokines, including IL-17 and IFNγ as well as increased expression of the cell surface markers CD25, CD69, and CD134.”
From The calm after the cytokine storm: lessons from the TGN1412 trial (2008) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These authors found that i.v. infusion of rats with JJ316, the rat functional equivalent of TGN1412 that had been instrumental in most of the relevant preclinical studies, caused a rapid redistribution of all CD4 + T cells from the periphery to the spleen and lymph nodes (5), and therefore, simulated the T cell lymphopenia observed in humans following TGN1412 administration.”
From The calm after the cytokine storm: lessons from the TGN1412 trial (2008) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Surprisingly, JJ316 infusion elicited only mildly elevated levels of TNFα and IFNγ in the serum of treated rats, which produced no discernable clinical effects and were several orders of magnitude below that seen in the TGN1412-treated subjects.”
From The calm after the cytokine storm: lessons from the TGN1412 trial (2008) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The authors showed, via intravital video microscopy, that T cell motility was dramatically reduced immediately following TGN1412 administration, suggesting that the observed T cell redistribution was a consequence of T cells becoming trapped in the secondary lymphoid organs.”
From The calm after the cytokine storm: lessons from the TGN1412 trial (2008) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In contrast, JJ316 treatment in the rats did not reproduce the massive cytokine storm observed following TGN1412 administration to the human volunteers.”
From The calm after the cytokine storm: lessons from the TGN1412 trial (2008) · cites this paper as [5]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
Matloubian, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., Allende, M. L., Proia, R. L., & Cyster, J. G. (2004) · Nature · doi:10.1038/nature02284 · Cited by 2,581
Transmembrane crosstalk between the extracellular matrix and the cytoskeleton
Geiger, B., Bershadsky, A., Pankov, R., & Yamada, K. M. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35099066 · Cited by 2,209
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors
Brinkmann, V., Davis, M. D., Heise, C. E., Albert, R., Cottens, S., Hof, R., Bruns, C., Prieschl, E., Baumruker, T., Hiestand, P., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200176200 · Cited by 1,504
CD69 acts downstream of interferon-α/β to inhibit S1P1 and lymphocyte egress from lymphoid organs
Shiow, L. R., Rosen, D. B., Brdičková, N., Xu, Y., An, J., Lanier, L. L., Cyster, J. G., & Matloubian, M. (2006) · Nature · doi:10.1038/nature04606 · Cited by 1,189
Mechanisms of suppression by suppressor T cells
von Boehmer, H. (2005) · Nature Immunology · doi:10.1038/ni1180 · Cited by 1,007
Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs
Cyster, J. G. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115628 · Cited by 856
Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor
Reichardt, H. M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.7168 · Cited by 429
Self-citationRegulation of T-cell activation by the cytoskeleton
Billadeau, D. D., Nolz, J. C., & Gomez, T. S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2021 · Cited by 388
Alternative Vascularization Mechanisms in Cancer
Döme, B., Hendrix, M. J. C., Paku, S., Tóvári, J., & Tímár, J. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060302 · Cited by 359
Cited by
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
Weirather, J., Hofmann, U. D. W., Beyersdorf, N., Ramos, G. C., Vogel, B., Frey, A., Ertl, G., Kerkau, T., & Frantz, S. (2014) · Circulation Research · doi:10.1161/circresaha.115.303895 · Cited by 699
Immunopathogenesis and treatment of cytokine storm in COVID-19
Kim, J. S., Lee, J. Y., Yang, J. W., Lee, K. H., Effenberger, M., Szpirt, W., Kronbichler, A., & Shin, J. I. (2021) · Theranostics · doi:10.7150/thno.49713 · Cited by 463
“anti-CD28 super-agonistic antibody, JJ316, to experimental rats and observed responses [19].”
BackgroundDelivering safer immunotherapies for cancer
Milling, L., Zhang, Y., & Irvine, D. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.011 · Cited by 305
Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis
Kishore, M., Cheung, K. C. P., Fu, H., Bonacina, F., Wang, G., Coe, D., Ward, E. J., Colamatteo, A., Jangani, M., Baragetti, A., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.10.017 · Cited by 276
Monoclonal antibody-induced cytokine-release syndrome
Bugelski, P. J., Achuthanandam, R., Capocasale, R. J., Treacy, G., & Bouman-Thio, E. (2009) · Expert Review of Clinical Immunology · doi:10.1586/eci.09.31 · Cited by 161
Tarrant, J. M. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq134 · Cited by 141
“A surrogate anti-rat-CD28 antibody (JJ316) also failed to elicit a cytokine storm in the rat (Muller et al., 2008).”
BackgroundRömer, P. S., Berr, S., Avota, E., Na, S.-Y., Battaglia, M., ten Berge, I., Einsele, H., & Hünig, T. (2011) · Blood · doi:10.1182/blood-2010-12-319780 · Cited by 153
Penzo, M., Molteni, R., Suda, T., Samaniego, S., Raucci, A., Habiel, D. M., Miller, F., Jiang, H.-P., Li, J., Pardi, R., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903131 · Cited by 101
Horvath, C. J., & Milton, M. N. (2009) · Toxicologic Pathology · doi:10.1177/0192623309332986 · Cited by 87
“However, JJ316 was subsequently shown to induce complete depletion of circulating T cells almost instantaneously (within 2 minutes) after IV administration (Müller et al. 2008).”
BackgroundIntracellular Signals of T Cell Costimulation
Song, J. J., Lei, F., Xiong, X., & Haque, R. (2008) · Cellular and Molecular Immunology · doi:10.1038/cmi.2008.30 · Cited by 80
“Volume 5 Number 4 August 2008 altering bcl-2 and caspase protein function, and enhancing memory T cell development (4, 5).”
BackgroundRapid Regulatory T-Cell Response Prevents Cytokine Storm in CD28 Superagonist Treated Mice
Gogishvili, T., Langenhorst, D., Lühder, F., Elias, F., Elflein, K., Dennehy, K. M., Gold, R., & Hünig, T. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004643 · Cited by 79
“In keeping with these results and our previously published model [6], a transient induction of cytokine mRNA, but no systemic cytokine release, was recently reported for CD28SA treated rats [34].”
ResultThe calm after the cytokine storm: lessons from the TGN1412 trial
St. Clair, E. W. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35382 · Cited by 79
Considerations for the development of therapeutic monoclonal antibodies
Swann, P. G., Tolnay, M., Muthukkumar, S., Shapiro, M. A., Rellahan, B. L., & Clouse, K. A. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.05.013 · Cited by 78
CD28 Superagonists: What Makes the Difference in Humans?
Schraven, B. L., & Kalinke, U. (2008) · Immunity · doi:10.1016/j.immuni.2008.04.003 · Cited by 63
Schabowsky, R.-H., Elpek, K. G., Madireddi, S., Sharma, R. K., Yolcu, E. S., Bandura‐Morgan, L., Miller, R. E., MacLeod, K. J., Mittler, R. S., & Shirwan, H. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.09.127 · Cited by 58
“This initial wave of effector T cell activation was followed by a second wave of activation that resulted in the preferential expansion of Treg cells, and there was no detectable increase in secreted pro-inflammatory cytokines [47].”
Backgroundvan den Brandt, J., Fischer, H. J., Walter, L., Hünig, T., Klöting, I., & Reichardt, H. M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000462 · Cited by 54
“Furthermore, treatment with JJ316 increases the functional activity of Treg cells and should therefore enhance their therapeutic efficiency (28, 41).”
BackgroundMethodSelf-citationA more selective costimulatory blockade of the CD28-B7 pathway
Poirier, N., Blancho, G., & Vanhove, B. (2010) · Transplant International · doi:10.1111/j.1432-2277.2010.01176.x · Cited by 54
“In rodents, CD28SA-induced lymphopenia was well tolerated and not associated with a massive release of pro-inflammatory mediators [78,81], probably controlled and regulated by Treg expansion.”
BackgroundInfluentialLinker, R. A., & Lee, D.-H. (2009) · Experimental & Translational Stroke Medicine · doi:10.1186/2040-7378-1-5 · Cited by 43
CD28-Specific Immunomodulating Antibodies: What Can Be Learned From Experimental Models?
Poirier, N., Blancho, G., & Vanhove, B. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04032.x · Cited by 52
“In fact, they elicit two qualitatively distinct waves of T-cell activation: a first phase of Teff polyclonal activation, followed by a second phase of Treg expansion dependent on paracrine IL-2 secretion from stimulated Teff (12,13).”
BackgroundInfluentialRegulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis
Kishore, M., Cheung, K. C.-P., Fu, H., Bonacina, F., Wang, G., Coe, D., Ward, E. J., Colamatteo, A., Jangani, M., Baragetti, A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.034 · Cited by 51
Mechanisms of Adverse Drug Reactions to Biologics
Clarke, J. B. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-00663-0_16 · Cited by 48
“Further supporting a pharmacologically mediated role for TGN1412-mediated toxicity, studies with a superagonist CD28 antibody (JJ316) in rats demonstrated an analogous response with initial T cell activation, acute lymphopenia, and cytokine release when the superagonist is administered to rats (Muller et al. 2008).”
BackgroundTranscriptional regulation of Foxp3 gene: Multiple signal pathways on the road
Shen, Z., Chen, L., Hao, F., & Wu, J. (2009) · Medicinal Research Reviews · doi:10.1002/med.20152 · Cited by 48
TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model
Weißmüller, S., Kronhart, S., Kreuz, D., Schnierle, B. S., Kalinke, U., Kirberg, J., Hanschmann, K.-M. O., & Waibler, Z. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149093 · Cited by 45
“07 ng/ml) expression within 24 hours after injection [32].”
BackgroundResultInfluentialTischner, D., Theiss, J., Karabinskaya, A., van den Brandt, J., Reichardt, S. D., Karow, U., Herold, M. J., Lühder, F., Utermöhlen, O., & Reichardt, H. M. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100911 · Cited by 37
“Infiltrating cells from the liver of aGvHD mice were isolated as described (27).”
BackgroundSelf-citationMüller, N., Fischer, H. J., Tischner, D., van den Brandt, J., & Reichardt, H. M. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201520 · Cited by 35
“To address this question, we transferred eGFPtransgenic effector T cells into naive rats (18, 20) and injected the animals i.”
MethodSelf-citationOtt, M., Avendaño-Guzmán, E., Ullrich, E., Dreyer, C., Strauss, J., Harden, M., Schön, M., Schön, M., Bernhardt, G., Stadelmann, C., et al. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1437-0 · Cited by 23
Walker, M., Makropoulos, D., Achuthanandam, R., Arsdell, S. V., & Bugelski, P. J. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.06.001 · Cited by 27
“In some animal models release of cytokines has been seen, but rarely does it progress to clinically relevant CRS [3–6].”
BackgroundMedina, M. Á., Couturier, J. P., Feske, M. L., Mahne, A. E., Turner, M. A., Yu, X., Kozinetz, C. A., Orozco, A. F., Hutchison, A. T., Savidge, T., et al. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0511264 · Cited by 20
“This activation was also accompanied by unexpected alteration of T cell migratory patterns as a result of aberrant expression of adhesion molecules, such as CD62L and LFA-1, and immediately following this activation period, proliferation of the CD4 CD25 Foxp3 Tregs was observed [12].”
BackgroundInfluentialHuman and Mouse CD137 Have Predominantly Different Binding CRDs to Their Respective Ligands
Yi, L., Zhao, Y., Wang, X., Dai, M., Hellström, K. E., Hellström, I., & Zhang, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086337 · Cited by 17
“For example, two different mAbs to CD28, JJ316 and JJ319 trigger different functional signals via CD28 with JJ316 being a hypercostimulatory activating mAb [23].”
BackgroundEstimating the “First in human” dose – a revisit with particular emphases in oncology drugs
Tam, K. Y. (2013) · ADMET & DMPK · doi:10.5599/admet.1.4.10 · Cited by 15
Immune regulation by peripheral suppressor T cells induced upon homotypic T cell/T cell interactions
Thümmler, K., Leipe, J., Ramming, A., Schulze‐Koops, H., & Skapenko, A. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0310122 · Cited by 12
“These interactions, in turn, may enhance further the intracellular adhesion between the T cells by activating LFA-1 on the resting T cells [21].”
BackgroundAnalysis of cytokine release assay data using machine learning approaches
Xiong, F., Janko, M., Walker, M., Makropoulos, D., Weinstock, D., Kam, M., & Hrebien, L. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.07.024 · Cited by 9
Les complications « toxiques » liées à l’utilisation des anticorps monoclonaux
Pallardy, M. J. (2009) · médecine/sciences · doi:10.1051/medsci/200925121130 · Cited by 8
“ont montré en employant le JJ316 (équivalent du TGN1412 chez le rat), la présence de deux vagues d’activation des lymphocytes T [17].”
BackgroundSuperagonistic CD28 Protects against Renal Ischemic Injury by Expansion of Regulatory T-Cell
Liang, Y., Li, Y., Kuang, Q., Ding, X., Wei, Z., & Fang, Y. (2017) · American Journal of Nephrology · doi:10.1159/000470918 · Cited by 7
Critical Aspects of Integrated Nonclinical Drug Development
Koch, E., & Plassmann, S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803620-4.00002-5 · Cited by 6
Hillebrands, J., Rozing, J., & Visser, J. T. J. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1090132 · Cited by 5
The waves behind the TGN1412 storm
Tufet, M. (2008) · Nature reviews. Immunology · doi:10.1038/nri2320 · Cited by 5
CD28 Superagonist Shock and Blockage of Motogenic T Cell Cascade
Sundqvist, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.670864 · Cited by 2
“org 2 pseudopodia (2, 9), which mimics the appearance of arrested cells in rodents treated with superagonistic CD28 antibodies (15).”
BackgroundRoškar, Z., Dreisinger, M., Tič, P., Homšak, E., Bevc, S., & Goropevšek, A. (2023) · Biosensors · doi:10.3390/bios13050539 · Cited by 2
“Recent trials emphasized the importance of directly assessing the human immune response, and that not all of what we learn, for example, in rodents can be directly translated to humans [20,21].”
BackgroundEtablierung eines Entzündungsmodells an der isoliert perfundierten humanen Plazenta
Walther, S. (2010) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.11348
NEW BIOMARKERS AND MONITORING INTRACELLULAR SIGNALINGPATHWAYS IN AUTOIMMUNE DISEASES
Goropevšek, A., Homšak, E., Gorenjak, M., Malešič, I., Krajnc, I., & Čenčič, A. (2008) · Slovenian Medical Journal
Chan, S., Voskens, C., Lin, W., Schindler, D. G., Azimzadeh, A. M., Wang, L., Taylor, R. J., Strome, S. E., & Schulze, D. H. (2009) · Journal of Molecular Recognition · doi:10.1002/jmr.937
“…of a super-agonistic anti-CD28 mAb, underscore the importance of appropriate animal model choices in preclinical testing of therapeutic agents which alter the function of co-signaling pathways (Kenter and Cohen, 2006; Suntharalingam et al., 2006; Stebbings et al., 2007; Muller et al., 2008).”
BackgroundSpatiotemporal receptor dynamics during early T cell signaling
Fay, N. C. (2014) · eScholarship (California Digital Library)
Characterisation of RIG-I-like receptor agonists for dengue virus therapy or vaccination
Ho, V. C. Y. (2019) · doi:10.32657/10220/47846
“Rodent models used in the pre-clinical testing TGN1412 only showed moderate increase in serum cytokine levels, unlike in the human clinical trials where the increase was dramatic (Müller et al., 2008).”
MethodImmunometabolic profiling of CD4+ T cells in cattle
Eder, J. M. (2019) · Iowa State University Digital Repository (Iowa State University)
Schurich, A. (2009) · bonndoc (University of Bonn)
van den Brandt, J., & Reichardt, H. M. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1090133
Self-citationHaack, S. (2021) · Online Publication Service of Würzburg University (Würzburg University) · doi:10.25972/opus-23775
The Development, Indications, and the Safety of Monoclonal Antibodies
Güney, H. Z. (2023) · Lokman Hekim Health Sciences · doi:10.14744/lhhs.2023.12008
Koch, E., & Plassmann, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85704-8.00021-9
CD40 Stimulation and Antitumor Effects
Wilkins, D. E. C., & Murphy, W. J. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0170-5_13
Metadata
- Authors
- Müller, N., van den Brandt, J., Odoardi, F., Tischner, D., Herath, J., Flügel, A., & Reichardt, H. M.
- Affiliations
- University of Würzburg (DE)
- Max Planck Society (DE)
- Corresponding author
- Reichardt, Holger M.
- Venue
- Journal of Clinical Investigation
- Published
- 2008-04-01
- Volume
- 118
- Issue
- 4
- Pages
- 1405-1416
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2269726
- OpenAlex
- W2052306755
- Cited by
- 46
- References
- 30
- Citations by year
- 2024: 1 · 2023: 2 · 2021: 1 · 2020: 1 · 2019: 2 · 2017: 3 · 2016: 2 · 2014: 4 · 2013: 1 · 2012: 2
- FWCI
- 3.75
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Max Planck Institute for Plasma Physics (submittedVersion)
- Max Planck Digital Library (submittedVersion)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- Wilhelm Sander-Stiftung
- Deutsche Forschungsgemeinschaft (SFB455, 1.01.1/06/010)
- Georg-August-Universität Göttingen
- Gemeinnützige Hertie-Stiftung (1.01.1/06/010)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- T cell activation, T lymphopenia, T cell motility, CD11a/CD18, L-selectin, E-selectin, sphingosine-1-phosphate, regulatory T cells, Foxp3, T cell polarization, secondary lymphoid organs, T cell redistribution, autoimmune disease therapy, TGN1412, cytokine storm
- MeSH terms
- Animals, Antibodies, Cell Adhesion, Cell Movement, Cell Survival, Cytoskeleton, Lymphocyte Activation, Lymphoid Tissue, Lymphopenia, Male, Rats, Inbred Lew, T-Lymphocytes, Time Factors, Biomarkers, Up-Regulation, Cytokines, Cell Polarity, CD28 Antigens, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.